Highlights NewAmsterdam Pharma Company N.V. BOERSE MUENCHEN

Equities

KH6

NL00150012L7

Market Closed - BOERSE MUENCHEN Other stock markets 20:43:41 02/07/2024 BST			5-day change	1st Jan Change
19 ^EUR	+1.60%		+2.19%	0.00%

06-11	NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043	MT
06-10	Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043	06-11	MT
NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings	05-21	CI
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M	05-09	MT
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	04-09	CI
Newamsterdam Pharma Company N.V. Doses First Patient in Phase 3 Tandem Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with Hefh And/Or Ascvd	03-12	CI
NewAmsterdam Pharma Full Year 2023 Net Loss Widens, Revenue Drops	02-28	MT
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Newamsterdam Pharma Company N.V. Announces Initial Data from Phase 2A Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an Apoe4 Mutation	21/09/23	CI
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	07/08/23	CI
NewAmsterdam Pharma Company N.V. Provides Clinical Development Updates	07/08/23	CI
Newamsterdam Pharma Company N.V. Completes Enrollment in Pivotal Phase 3 Broadway Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia And/Or Established Atherosclerotic Cardiovascular Disease	25/07/23	CI
NewAmsterdam Pharma Company N.V. Announces Positive Topline Results from Phase 2B Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients	05/06/23	CI
NewAmsterdam Pharma Company N.V. Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023	03/06/23	CI
NewAmsterdam Pharma Company N.V. Provides Clinical Development Updates	08/05/23	CI
NewAmsterdam Pharma Completes Enrollment in Phase 3 Trial of Obicetrapib to Treat Heterozygous Familial Hypercholesterolemia	24/04/23	MT
Newamsterdam Pharma Completes Enrollment in Pivotal Phase 3 Brooklyn Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia	24/04/23	CI
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
NewAmsterdam Pharma Company N.V. Appoints John W. Smither as Independent Director	06/02/23	CI
Newamsterdam Pharma Company N.V. Announces Positive Results from Rose2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy	17/01/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NewAmsterdam Pharma Company N.V. BOERSE MUENCHEN

Equities

KH6

NL00150012L7

Highlights

Filters